Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of DASH CD19 CAR-T in R/R B-ALL
NCT05651191Phase 1Recruiting
- Sponsor
- Shanghai HRAIN Biotechnology
- Start
- Oct 2022
- Primary completion
- Sep 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DASH CD19 CAR-T in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Shanghai HRAIN Biotechnology. Primary endpoint: Dose Limited Toxicity. Started Oct 2022; status: recruiting.
02
Drugs
DASH CD19 CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05651191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651191.